Effect of Preloading With High Dose of Rosuvastatin on Serum Levels of Inflammatory Markers After Percutaneous Coronary Intervention

Autor(es):Mostrar menos -

Slhessarenko, Juliano R. ^[1] ; Hirata, Mario ^{[1, 2]} ; Sousa, Amanda ^[1] ; Bastos, Gisele M. ^[1] ; Higa, Elisa M. S. ^[3] ; Mouro, Margareth G. ^[3] ; Sobrera, Guilherme C. ^[2] ; Slhessarenko, Renata D. ^[4] ; Viana, Renata ^[1] ; Abizaid, Alexandre ^[1] ; Costa Jr, J. Ribamar

Afiliação do(s) autor(es)

^[1] Inst Dante Pazzanese Cardiol, Sao Paulo - Brazil

^[2] Sao Paulo Univ USP, Sao Paulo - Brazil

^[3] Fed Univ Sao Paulo UNIFESP, Sao Paulo - Brazil

^[4] Univ Fed Mato Grosso, Cuiaba - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF INVASIVE CARDIOLOGY; v. 32, n. 9, p. 335+, SEP 2020.
• Citações Web of Science: 0

Resumo

Objectives. We sought to assess the effects of a high loading dose of rosuvastatin (40 mg) on acute inflammatory response after coronary stenting. Methods. Patients with stable coronary disease without statin use (>= 7 days) and undergoing elective percutaneous coronary intervention (PCI) in a native coronary artery were randomized to receive a loading dose of rosuvastatin (n = 64) or not (n = 61). Blood samples were obtained before statin intake (time point A), 3 hours after medication (time point B), and 3 hours after PCI (time point C). The primary goal was the comparison in the variation of the serum inflammatory markers and their gene expression at the different time points between the two groups. Results. Baseline clinical, angiographic, and procedural characteristics did not significantly differ between the groups, except for the more frequent use of postdilation in the control group (73.4% vs 90.2%; P=.02). Patients pretreated with statin showed a reduction in the serum levels of interleukin (IL)-1 beta (Delta = -0.491 pg/mL; P-interaction<.001), IL-6 (Delta = -0.209 pg/mL; P-interaction<.001), and plasminogen activator inhibitor 1 (Delta = -1.573 pg/mL; P-interaction<.001) as well as in their genetic expression, which was not observed in the control group. Regarding high-sensitivity c-reactive protein, there was no significant variation in its value from time point A to C in patients pretreated with statin (P=.58) while it significantly increased in the control group ( P=.04). Conclusion. Among patients with stable coronary artery disease undergoing PCI with stents, pretreatment with high dose of rosuvastatin resulted in significant reduction in the serum levels of important inflammatory markers and their genetic expression. (AU)

• Processo FAPESP: 12/22989-1 - Efeitos da rosuvastatina sobre os mediadores da resposta inflamatória aguda IL-1, IL-6, IL-8, TNF-±, TGF-², MCP-1/CCL-2, PAI-1, proteína C reativa e óxido nítrico após implante coronariano de stent não-farmacológico
• Beneficiário: Alexandre Antônio Cunha Abizaid
• Modalidade de apoio: Auxílio à Pesquisa - Regular